Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva ...

Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

RHHBY (OTC:RHHBY)), a pharmaceutical giant with a market capitalization of $265.76 billion, saw its price target increased by Deutsche Bank (ETR:DBKGn) from CHF250.00 to CHF265.00, while the firm ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...